Partial
Partially Aligned
Patient Risk:
Low
Summary
Only one of the provided claims was assessed and it is supported by the supplied label excerpt. The remaining claims (brand/generic identity, indication scope/marketing details, and coverage of administration/monitoring/adverse effects) were not evaluated against label text and thus cannot be confirmed from the provided prescribing information.
Category Scores
Accurate Statements
CEREZYME (imiglucerase) is indicated for treatment of non-central nervous system (CNS) manifestations of Type 1 or Type 3 Gaucher disease in adults and pediatric patients.
Supported by Section 1 INDICATIONS AND USAGE: "CEREZYME is indicated for the treatment of non-central nervous system (CNS) manifestations of Type 1 or Type 3 Gaucher disease in adults and pediatric patients."
Unsupported Statements
Cerezyme is the brand name for imiglucerase.
No brand-name-to-generic identity statement was provided in the supplied label excerpts beyond naming CEREZYME (imiglucerase) in the evaluated claim/description text; the exact specific claim as written ("brand name for") was not directly evidenced in the provided excerpts.
Imiglucerase is an enzyme replacement therapy.
The supplied excerpts describe imiglucerase as a lysosomal enzyme and recombinant enzyme for injection, but do not explicitly use the term "enzyme replacement therapy".
Imiglucerase is used to treat Gaucher disease.
The supplied indication excerpt is specifically for CEREZYME, not imiglucerase generally; a direct statement "imiglucerase is used to treat Gaucher disease" was not explicitly provided.
Cerezyme has been marketed under Sanofi Genzyme.
No marketing/company history content was included in the supplied label excerpts.
Sanofi Genzyme is the manufacturer/marketer of record associated with Cerezyme.
No manufacturer/marketer-of-record information was included in the supplied label excerpts.
Cerezyme specifically refers to imiglucerase under the Sanofi Genzyme offering.
Sanofi Genzyme-specific framing was not supported by any provided label excerpts.
Details on how Cerezyme is given, typical monitoring, and adverse effects are covered in the prescribing information for the Sanofi Genzyme product.
While the excerpt includes "intended for intravenous use" and points to adverse reactions elsewhere in labeling, the claim is broadened to include "typical monitoring" and specifically references "Sanofi Genzyme product"; neither "typical monitoring" nor Sanofi Genzyme-specific coverage was supported by the provided excerpts.
Contradictions
Important Omissions
Verification of brand/generic identity and company/manufacturer-marketer statements (e.g., Sanofi Genzyme association) from the provided FDA label text.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only evaluated, label-supported claim is an indication statement. The other claims were not supported by the provided label excerpts and therefore could lead to informational inaccuracies, but no dosing/safety instruction errors were actually evidenced in the supplied evaluation.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims were not supported by the supplied FDA label excerpts (notably brand/company association and statements about enzyme replacement therapy/usage of imiglucerase).
Suggested Improvement
Assess each claim directly against the supplied label text/sections, and restrict statements to what is explicitly evidenced (or omit unverifiable manufacturer/marketing and monitoring/TERMINOLOGY claims when the provided label excerpt does not support them).